Kyung Hyun Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kyung Hyun Oh has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Fukushi Morishita
World Health Organization Regional Office for the Western Pacific, Manila, Philippines
6 shared publicationsKalpeshsinh Rahevar
World Health Organization Regional Office for the Western Pacific, Manilla, Philippines
4 shared publicationsManami Yanagawa
World Health Organization Regional Office for the Western Pacific, Manila, Philippines
3 shared publications- Fukushi Morishita
World Health Organization Regional Office for the Western Pacific, Manila, Philippines
2 shared publications - Hee Jin Kim
Central Training Institute, Korean National Tuberculosis Association, Seoul, Korea
2 shared publications - Hongjo Choi
Division of Health Policy and Management, Korea University College of Health Science, Seoul, Republic of Korea
2 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Springer Nature in BMC Public Health
Costs faced by households affected by tuberculosis in the Republic of Korea: a mixed-methods study
Background: Tuberculosis (TB) continues to impose substantial financial hardship on affected households in low- and middle-income countries. Until recently, no published evidence was available from high-income countries. This study presents the first national TB household cost survey conducted in the Republic of Korea, a high-income country, to assess the magnitude and drivers of catastrophic costs and explore underlying socioeconomic mechanisms. Methods: A mixed-methods study was conducted in 2024–2025. Adult patients with drug-susceptible TB (DS-TB) and drug-resistant TB (DR-TB) were recruited from selected hospitals nationwide. Structured questionnaires quantified direct medical, non-medical, and indirect costs. Catastrophic costs were defined as total TB-related expenditure exceeding 20% of pre-TB annual household income. Quality assurance included interviewer training, standardised data collection protocols, and supervisory oversight during data collection. For the qualitative component, semi-structured in-depth interviews were conducted with purposively selected participants and analysed using a framework approach. Results: A total of 157 patients were included (140 DS-TB and 17 DR-TB), alongside five qualitative interviewees. Mean total costs per TB episode were USD 4,515 (95% CI, 3,473–5,557) for DS-TB and USD 7,915 (95% CI, 4,948–10,882) for DR-TB. Nutritional supplements were the largest single cost driver (38.2% of the total cost for DS-TB and 53.8% for DR-TB), followed by post-diagnosis income loss. Catastrophic costs affected 41.4% of DS-TB and 52.9% of DR-TB households. Qualitative findings revealed widespread employment disruption, sustained income loss, coping through dissaving, and psychosocial distress. Conclusions: Despite comprehensive health insurance and free TB medical care, TB-affected households in Korea face substantial non-medical and indirect costs. Eliminating catastrophic costs will require social protection measures addressing income loss, caregiving demands, and non-medical expenditures alongside universal health coverage.
- 7 October 2026
- Published by Springer Nature in BMC Public Health
Open AccessCosts faced by households affected by tuberculosis in the Republic of Korea: a mixed-methods study
Background: Tuberculosis (TB) continues to impose substantial financial hardship on affected households in low- and middle-income countries. Until recently, no published evidence was available from high-income countries. This study presents the first national TB household cost survey conducted in the Republic of Korea, a high-income country, to assess the magnitude and drivers of catastrophic costs and explore underlying socioeconomic mechanisms. Methods: A mixed-methods study was conducted in 2024–2025. Adult patients with drug-susceptible TB (DS-TB) and drug-resistant TB (DR-TB) were recruited from selected hospitals nationwide. Structured questionnaires quantified direct medical, non-medical, and indirect costs. Catastrophic costs were defined as total TB-related expenditure exceeding 20% of pre-TB annual household income. Quality assurance included interviewer training, standardised data collection protocols, and supervisory oversight during data collection. For the qualitative component, semi-structured in-depth interviews were conducted with purposively selected participants and analysed using a framework approach. Results: A total of 157 patients were included (140 DS-TB and 17 DR-TB), alongside five qualitative interviewees. Mean total costs per TB episode were USD 4,515 (95% CI, 3,473–5,557) for DS-TB and USD 7,915 (95% CI, 4,948–10,882) for DR-TB. Nutritional supplements were the largest single cost driver (38.2% of the total cost for DS-TB and 53.8% for DR-TB), followed by post-diagnosis income loss. Catastrophic costs affected 41.4% of DS-TB and 52.9% of DR-TB households. Qualitative findings revealed widespread employment disruption, sustained income loss, coping through dissaving, and psychosocial distress. Conclusions: Despite comprehensive health insurance and free TB medical care, TB-affected households in Korea face substantial non-medical and indirect costs. Eliminating catastrophic costs will require social protection measures addressing income loss, caregiving demands, and non-medical expenditures alongside universal health coverage.
- Open Access
- 22 May 2026
- Published by Elsevier in Public Health
- Vol. 257, 106339
Pregnancy data in tuberculosis surveillance: Practices, priorities and perspectives from national TB programs in the Western Pacific and South-East Asia
- 22 May 2026
- Published by Elsevier in Public Health
- Vol. 257, 106339
Open AccessPregnancy data in tuberculosis surveillance: Practices, priorities and perspectives from national TB programs in the Western Pacific and South-East Asia
- Open Access
- 18 May 2026
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 54 (1)
Progress in tuberculosis diagnosis and laboratory services in the Western Pacific Region: a situational analysis of seven high tuberculosis burden countries
Background: Timely, accurate tuberculosis (TB) diagnostics and strong laboratory networks are critical for providing high-quality TB care. In the Western Pacific Region, available resources, TB burdens, and access to TB testing vary dramatically between countries. To understand the current regional situation, we described TB diagnostic test availability and laboratory services in seven countries with high TB burdens in the Western Pacific Region: Main text: In 2024, World Health Organization’s (WHO) Western Pacific Regional Office conducted an assessment of TB diagnostic test availability and laboratory services in seven countries with high TB burdens: Cambodia, China, Lao People’s Democratic Republic, Mongolia, Philippines, Papua New Guinea, and Viet Nam. Standardised surveys were sent to members of country national tuberculosis programmes, and follow-up interviews were conducted. An in-person workshop was attended where preliminary findings were presented and updated, if necessary. The exercise revealed a high uptake of WHO-endorsed rapid molecular tests for TB detection, although the use of smear microscopy persists in most countries’ remote areas. Regarding drug susceptibility testing, both molecular and phenotypic methods are employed. Testing for first-line TB drug resistance is generally available, but currently, testing capacity for new and re-purposed drugs remains limited. Most countries provide TB testing at district-level facilities in conjunction with well-established specimen transport networks, with laboratories utilising a mix of paper and electronic databases. Comprehensive TB and drug-resistance testing at peripheral settings remains a rarity. Conclusions: The Western Pacific Region has invested significantly in TB testing and laboratory services. To ensure everyone in the region has access to TB diagnostics, these efforts must be maintained.
- 18 May 2026
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 54 (1)
Open AccessProgress in tuberculosis diagnosis and laboratory services in the Western Pacific Region: a situational analysis of seven high tuberculosis burden countries
Background: Timely, accurate tuberculosis (TB) diagnostics and strong laboratory networks are critical for providing high-quality TB care. In the Western Pacific Region, available resources, TB burdens, and access to TB testing vary dramatically between countries. To understand the current regional situation, we described TB diagnostic test availability and laboratory services in seven countries with high TB burdens in the Western Pacific Region: Main text: In 2024, World Health Organization’s (WHO) Western Pacific Regional Office conducted an assessment of TB diagnostic test availability and laboratory services in seven countries with high TB burdens: Cambodia, China, Lao People’s Democratic Republic, Mongolia, Philippines, Papua New Guinea, and Viet Nam. Standardised surveys were sent to members of country national tuberculosis programmes, and follow-up interviews were conducted. An in-person workshop was attended where preliminary findings were presented and updated, if necessary. The exercise revealed a high uptake of WHO-endorsed rapid molecular tests for TB detection, although the use of smear microscopy persists in most countries’ remote areas. Regarding drug susceptibility testing, both molecular and phenotypic methods are employed. Testing for first-line TB drug resistance is generally available, but currently, testing capacity for new and re-purposed drugs remains limited. Most countries provide TB testing at district-level facilities in conjunction with well-established specimen transport networks, with laboratories utilising a mix of paper and electronic databases. Comprehensive TB and drug-resistance testing at peripheral settings remains a rarity. Conclusions: The Western Pacific Region has invested significantly in TB testing and laboratory services. To ensure everyone in the region has access to TB diagnostics, these efforts must be maintained.
- Open Access
- 12 March 2026
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 54 (1) , 47
Towards universal social protection for people affected by tuberculosis in the Western Pacific Region: a social protection baseline assessment and policy entry points
Background: Achieving universal social protection (SP) coverage for people affected by tuberculosis (TB) is increasingly recognised as an essential component of its response, as well as other diseases of poverty. Realising this goal requires to clearly understand the SP needs of people affected by TB and to identify means to maximise their access to existing or new SP benefits in an efficient, effective, and sustainable manner. Main body: To address these questions, between 2022 and 2023, the WHO Western Pacific Regional office conducted the first SP baseline assessment for people affected by TB in Mongolia, Lao People’s Democratic Republic, the Philippines, Cambodia, and Viet Nam. This exercise encompassed a desk review of SP programmes operating in these countries, followed by an expert consultation to discuss barriers and entry points to expand SP coverage among people affected by TB. Overall evidence gathered from publicly available reports and publications suggests that existing SP programmes in these countries are insufficiently accessible and inadequate to meet the needs of people affected by TB. Most countries provide TB-specific benefits only to people with multidrug-resistant TB, leaving most people with TB unserved. The most reported barriers to access to SP included lack of awareness, stigma, poverty, as well as programmes’ fragmentation, and administrative and financial constraints. Identified solutions included raising awareness about SP, extending TB-specific SP benefits to all people with TB in need, advocating for a better inclusion of people with TB into existing governmental programmes, and strengthening the referral system across the health and SP sectors. Conclusions: By identifying concrete policy entry points and actionable solutions, this SP baseline assessment provided a foundation for these five countries to embed social protection more systematically into their national TB responses. Ideally, this effort should now be replicated in all high TB-burden countries willing to achieve universal SP coverage among people affected by TB. The lessons that emerged from this baseline assessment are consistent with the recommended actions and principles underlying the Western Pacific Regional Framework for Reaching the Unreached and are thus transferrable to other diseases of poverty.
- 12 March 2026
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 54 (1) , 47
Open AccessTowards universal social protection for people affected by tuberculosis in the Western Pacific Region: a social protection baseline assessment and policy entry points
Background: Achieving universal social protection (SP) coverage for people affected by tuberculosis (TB) is increasingly recognised as an essential component of its response, as well as other diseases of poverty. Realising this goal requires to clearly understand the SP needs of people affected by TB and to identify means to maximise their access to existing or new SP benefits in an efficient, effective, and sustainable manner. Main body: To address these questions, between 2022 and 2023, the WHO Western Pacific Regional office conducted the first SP baseline assessment for people affected by TB in Mongolia, Lao People’s Democratic Republic, the Philippines, Cambodia, and Viet Nam. This exercise encompassed a desk review of SP programmes operating in these countries, followed by an expert consultation to discuss barriers and entry points to expand SP coverage among people affected by TB. Overall evidence gathered from publicly available reports and publications suggests that existing SP programmes in these countries are insufficiently accessible and inadequate to meet the needs of people affected by TB. Most countries provide TB-specific benefits only to people with multidrug-resistant TB, leaving most people with TB unserved. The most reported barriers to access to SP included lack of awareness, stigma, poverty, as well as programmes’ fragmentation, and administrative and financial constraints. Identified solutions included raising awareness about SP, extending TB-specific SP benefits to all people with TB in need, advocating for a better inclusion of people with TB into existing governmental programmes, and strengthening the referral system across the health and SP sectors. Conclusions: By identifying concrete policy entry points and actionable solutions, this SP baseline assessment provided a foundation for these five countries to embed social protection more systematically into their national TB responses. Ideally, this effort should now be replicated in all high TB-burden countries willing to achieve universal SP coverage among people affected by TB. The lessons that emerged from this baseline assessment are consistent with the recommended actions and principles underlying the Western Pacific Regional Framework for Reaching the Unreached and are thus transferrable to other diseases of poverty.
- Open Access
- 2 September 2025
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 53 (1) , 1-12
Progress and challenges in tuberculosis preventive treatment in the Western Pacific Region: a situational analysis of seven high tuberculosis burden countries
Background: Tuberculosis preventive treatment (TPT) can avert progression from infection to disease, yet scale-up across the World Health Organization Western Pacific Region is patchy. To guide acceleration, we assessed progress, challenges and responses in seven high-burden countries—Cambodia, China, Lao People’s Democratic Republic (PDR), Mongolia, Papua New Guinea, the Philippines and Viet Nam—drawing on 2015–2023 programme data, structured questionnaires, follow-up interviews and a regional validation workshop. Main body: Six of the seven countries have issued national TPT guidelines and five now offer shorter rifapentine- or rifampicin-based regimens. The number of people started on TPT rose sharply in most settings, driven by household contacts aged ≥ 5 years in Cambodia, Mongolia and the Philippines and by people living with HIV in Lao PDR and Papua New Guinea. However, coverage of children under five and other high-risk groups remains low. Cascade analysis revealed major attrition between screening and TPT initiation. Key obstacles, viewed through a socio-ecological lens, include: individual complacency, fear of adverse events and limited provider confidence; stigma and consent barriers in migrant households; intermittent staff training, medicine stock-outs and weak digital tools; long journeys to health facilities; and policy–practice gaps such as the absence of child-friendly formulations and non-notification of tuberculosis infection. Countries and partners endorsed a tiered package combining patient-centred counselling, mobile reminders, shorter paediatric regimens, stigma-reduction campaigns and remote e-consent. Health systems will reinforce staff training, digital supply-chain and adherence tools, while decentralised one-stop outreach and community health-workers extend coverage. A multisector task force will fast-track paediatric fixed-dose registration, make infection notifiable and absorb preventive treatment costs into national budgets and insurance schemes. Conclusions: The introduction of shorter regimens and rising enrolment confirm that rapid gains are achievable, yet wide disparities persist across age groups, risk categories and care-cascade stages. Implementing the agreed client, community, institutional and policy interventions—backed by integrated governance and sustainable domestic funding—can convert TPT from a promising guideline into a routine, life-saving component of primary health care throughout the Western Pacific Region.
- 2 September 2025
- Published by Springer Nature in Tropical Medicine and Health
- Vol. 53 (1) , 1-12
Open AccessProgress and challenges in tuberculosis preventive treatment in the Western Pacific Region: a situational analysis of seven high tuberculosis burden countries
Background: Tuberculosis preventive treatment (TPT) can avert progression from infection to disease, yet scale-up across the World Health Organization Western Pacific Region is patchy. To guide acceleration, we assessed progress, challenges and responses in seven high-burden countries—Cambodia, China, Lao People’s Democratic Republic (PDR), Mongolia, Papua New Guinea, the Philippines and Viet Nam—drawing on 2015–2023 programme data, structured questionnaires, follow-up interviews and a regional validation workshop. Main body: Six of the seven countries have issued national TPT guidelines and five now offer shorter rifapentine- or rifampicin-based regimens. The number of people started on TPT rose sharply in most settings, driven by household contacts aged ≥ 5 years in Cambodia, Mongolia and the Philippines and by people living with HIV in Lao PDR and Papua New Guinea. However, coverage of children under five and other high-risk groups remains low. Cascade analysis revealed major attrition between screening and TPT initiation. Key obstacles, viewed through a socio-ecological lens, include: individual complacency, fear of adverse events and limited provider confidence; stigma and consent barriers in migrant households; intermittent staff training, medicine stock-outs and weak digital tools; long journeys to health facilities; and policy–practice gaps such as the absence of child-friendly formulations and non-notification of tuberculosis infection. Countries and partners endorsed a tiered package combining patient-centred counselling, mobile reminders, shorter paediatric regimens, stigma-reduction campaigns and remote e-consent. Health systems will reinforce staff training, digital supply-chain and adherence tools, while decentralised one-stop outreach and community health-workers extend coverage. A multisector task force will fast-track paediatric fixed-dose registration, make infection notifiable and absorb preventive treatment costs into national budgets and insurance schemes. Conclusions: The introduction of shorter regimens and rising enrolment confirm that rapid gains are achievable, yet wide disparities persist across age groups, risk categories and care-cascade stages. Implementing the agreed client, community, institutional and policy interventions—backed by integrated governance and sustainable domestic funding—can convert TPT from a promising guideline into a routine, life-saving component of primary health care throughout the Western Pacific Region.
- Top Cited PapersOpen Access
- 20 April 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 36, 100770
Tuberculosis in older adults: challenges and best practices in the Western Pacific Region
- 20 April 2023
- Published by Elsevier in The Lancet Regional Health - Western Pacific
- Vol. 36, 100770
Top Cited PapersOpen AccessTuberculosis in older adults: challenges and best practices in the Western Pacific Region
- Open Access
- 7 November 2022
- Published by World Health Organization, Western Pacific Regional Office in Western Pacific Surveillance and Response Journal
- Vol. 13 (4) , 12-23
Progress on diagnosis and treatment of drug-resistant tuberculosis in line with World Health Organization recommendations in six priority countries in the Western Pacific Region
Background: Diagnosis and treatment of drug-resistant tuberculosis (DR-TB) have radically changed in accordance with recommendations from the World Health Organization (WHO) in the past decade, allowing rapid and simple diagnosis and shorter treatment duration with new and repurposed drugs. Methods: A descriptive analysis of the status and progress of DR-TB diagnosis and treatment in six priority countries in the Western Pacific Region was conducted using information from interviews with countries and the WHO TB database. Results: Over the past decade, the use of Xpert MTB/RIF has increased in the six priority countries, in parallel with implementation of national policies and algorithms to use Xpert MTB/RIF as an initial diagnostic test for TB and detection of rifampicin resistance. This has resulted in increases in the number of people diagnosed with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB). Shorter treatment regimens with new and repurposed drugs have also been adopted for MDR/RR-TB cases, alongside a decentralized model of care, leading to improved treatment outcomes. Discussion: The Western Pacific Region has achieved considerable progress in the diagnosis and treatment of DR-TB, in line with the evolving WHO recommendations in the past decade. The continued commitment of Member States is needed to address remaining challenges, such as the impact of the coronavirus disease pandemic, suboptimal management and health system issues.
- 7 November 2022
- Published by World Health Organization, Western Pacific Regional Office in Western Pacific Surveillance and Response Journal
- Vol. 13 (4) , 12-23
Open AccessProgress on diagnosis and treatment of drug-resistant tuberculosis in line with World Health Organization recommendations in six priority countries in the Western Pacific Region
Background: Diagnosis and treatment of drug-resistant tuberculosis (DR-TB) have radically changed in accordance with recommendations from the World Health Organization (WHO) in the past decade, allowing rapid and simple diagnosis and shorter treatment duration with new and repurposed drugs. Methods: A descriptive analysis of the status and progress of DR-TB diagnosis and treatment in six priority countries in the Western Pacific Region was conducted using information from interviews with countries and the WHO TB database. Results: Over the past decade, the use of Xpert MTB/RIF has increased in the six priority countries, in parallel with implementation of national policies and algorithms to use Xpert MTB/RIF as an initial diagnostic test for TB and detection of rifampicin resistance. This has resulted in increases in the number of people diagnosed with multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB). Shorter treatment regimens with new and repurposed drugs have also been adopted for MDR/RR-TB cases, alongside a decentralized model of care, leading to improved treatment outcomes. Discussion: The Western Pacific Region has achieved considerable progress in the diagnosis and treatment of DR-TB, in line with the evolving WHO recommendations in the past decade. The continued commitment of Member States is needed to address remaining challenges, such as the impact of the coronavirus disease pandemic, suboptimal management and health system issues.
- Open Access
- 14 July 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (7) , e1003717
Evaluating the impact of the nationwide public–private mix (PPM) program for tuberculosis under National Health Insurance in South Korea: A difference in differences analysis
Background: Public–private mix (PPM) programs on tuberculosis (TB) have a critical role in engaging and integrating the private sector into the national TB control efforts in order to meet the End TB Strategy targets. South Korea’s PPM program can provide important insights on the long-term impact and policy gaps in the development and expansion of PPM as a nationwide program. Methods and findings: Healthcare is privatized in South Korea, and a majority (80.3% in 2009) of TB patients sought care in the private sector. Since 2009, South Korea has rapidly expanded its PPM program coverage under the National Health Insurance (NHI) scheme as a formal national program with dedicated PPM nurses managing TB patients in both the private and public sectors. Using the difference in differences (DID) analytic framework, we compared relative changes in TB treatment outcomes—treatment success (TS) and loss to follow-up (LTFU)—in the private and public sector between the 2009 and 2014 TB patient cohorts. Propensity score matching (PSM) using the kernel method was done to adjust for imbalances in the covariates between the 2 population cohorts. The 2009 cohort included 6,195 (63.0% male, 37.0% female; mean age: 42.1) and 27,396 (56.1% male, 43.9% female; mean age: 45.7) TB patients in the public and private sectors, respectively. The 2014 cohort included 2,803 (63.2% male, 36.8% female; mean age: 50.1) and 29,988 (56.5% male, 43.5% female; mean age: 54.7) patients. In both the private and public sectors, the proportion of patients with transfer history decreased (public: 23.8% to 21.7% and private: 20.8% to 17.6%), and bacteriological confirmed disease increased (public: 48.9% to 62.3% and private: 48.8% to 58.1%) in 2014 compared to 2009. After expanding nationwide PPM, absolute TS rates improved by 9.10% (87.5% to 93.4%) and by 13.6% (from 70.3% to 83.9%) in the public and private sectors. Relative to the public, the private saw 4.1% (95% confidence interval [CI] 2.9% to 5.3%, p-value < 0.001) and −8.7% (95% CI −9.7% to −7.7%, p-value <0.001) higher rates of improvement in TS and reduction in LTFU. Treatment outcomes did not improve in patients who experienced at least 1 transfer during their TB treatment. Study limitations include non-longitudinal nature of our original dataset, inability to assess the regional disparities, and verify PPM program’s impact on TB mortality. Conclusions: We found that the nationwide scale-up of the PPM program was associated with improvements in TB treatment outcomes in the private sector in South Korea. Centralized financial governance and regulatory mechanisms were integral in facilitating the integration of highly diverse South Korean private sector into the national TB control program and scaling up of the PPM intervention nationwide. However, TB care gaps continued to exist for patients who transferred at least once during their treatment. These programmatic gaps may be improved through reducing administrative hurdles and making programmatic amendments that can help facilitate management TB patients between institutions and healthcare sectors, as well as across administrative regions.
- 14 July 2021
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 18 (7) , e1003717
Open AccessEvaluating the impact of the nationwide public–private mix (PPM) program for tuberculosis under National Health Insurance in South Korea: A difference in differences analysis
Background: Public–private mix (PPM) programs on tuberculosis (TB) have a critical role in engaging and integrating the private sector into the national TB control efforts in order to meet the End TB Strategy targets. South Korea’s PPM program can provide important insights on the long-term impact and policy gaps in the development and expansion of PPM as a nationwide program. Methods and findings: Healthcare is privatized in South Korea, and a majority (80.3% in 2009) of TB patients sought care in the private sector. Since 2009, South Korea has rapidly expanded its PPM program coverage under the National Health Insurance (NHI) scheme as a formal national program with dedicated PPM nurses managing TB patients in both the private and public sectors. Using the difference in differences (DID) analytic framework, we compared relative changes in TB treatment outcomes—treatment success (TS) and loss to follow-up (LTFU)—in the private and public sector between the 2009 and 2014 TB patient cohorts. Propensity score matching (PSM) using the kernel method was done to adjust for imbalances in the covariates between the 2 population cohorts. The 2009 cohort included 6,195 (63.0% male, 37.0% female; mean age: 42.1) and 27,396 (56.1% male, 43.9% female; mean age: 45.7) TB patients in the public and private sectors, respectively. The 2014 cohort included 2,803 (63.2% male, 36.8% female; mean age: 50.1) and 29,988 (56.5% male, 43.5% female; mean age: 54.7) patients. In both the private and public sectors, the proportion of patients with transfer history decreased (public: 23.8% to 21.7% and private: 20.8% to 17.6%), and bacteriological confirmed disease increased (public: 48.9% to 62.3% and private: 48.8% to 58.1%) in 2014 compared to 2009. After expanding nationwide PPM, absolute TS rates improved by 9.10% (87.5% to 93.4%) and by 13.6% (from 70.3% to 83.9%) in the public and private sectors. Relative to the public, the private saw 4.1% (95% confidence interval [CI] 2.9% to 5.3%, p-value < 0.001) and −8.7% (95% CI −9.7% to −7.7%, p-value <0.001) higher rates of improvement in TS and reduction in LTFU. Treatment outcomes did not improve in patients who experienced at least 1 transfer during their TB treatment. Study limitations include non-longitudinal nature of our original dataset, inability to assess the regional disparities, and verify PPM program’s impact on TB mortality. Conclusions: We found that the nationwide scale-up of the PPM program was associated with improvements in TB treatment outcomes in the private sector in South Korea. Centralized financial governance and regulatory mechanisms were integral in facilitating the integration of highly diverse South Korean private sector into the national TB control program and scaling up of the PPM intervention nationwide. However, TB care gaps continued to exist for patients who transferred at least once during their treatment. These programmatic gaps may be improved through reducing administrative hurdles and making programmatic amendments that can help facilitate management TB patients between institutions and healthcare sectors, as well as across administrative regions.